ATE352317T1 - Therapeutische behandlung von eosinophilie durch verwendung von chymase-inhibitoren als aktiven bestandteilen - Google Patents

Therapeutische behandlung von eosinophilie durch verwendung von chymase-inhibitoren als aktiven bestandteilen

Info

Publication number
ATE352317T1
ATE352317T1 AT01906225T AT01906225T ATE352317T1 AT E352317 T1 ATE352317 T1 AT E352317T1 AT 01906225 T AT01906225 T AT 01906225T AT 01906225 T AT01906225 T AT 01906225T AT E352317 T1 ATE352317 T1 AT E352317T1
Authority
AT
Austria
Prior art keywords
eosinophily
active ingredients
therapeutic treatment
chymase inhibitors
treatment
Prior art date
Application number
AT01906225T
Other languages
English (en)
Inventor
Harukazu Fukami
Naohiro Watanabe
Original Assignee
Daiichi Asubio Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Asubio Pharma Co Ltd filed Critical Daiichi Asubio Pharma Co Ltd
Application granted granted Critical
Publication of ATE352317T1 publication Critical patent/ATE352317T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01906225T 2000-02-22 2001-02-22 Therapeutische behandlung von eosinophilie durch verwendung von chymase-inhibitoren als aktiven bestandteilen ATE352317T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000050487 2000-02-22

Publications (1)

Publication Number Publication Date
ATE352317T1 true ATE352317T1 (de) 2007-02-15

Family

ID=18572266

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01906225T ATE352317T1 (de) 2000-02-22 2001-02-22 Therapeutische behandlung von eosinophilie durch verwendung von chymase-inhibitoren als aktiven bestandteilen

Country Status (11)

Country Link
US (1) US6677344B2 (de)
EP (1) EP1174151B1 (de)
KR (1) KR20010109526A (de)
CN (1) CN1245978C (de)
AT (1) ATE352317T1 (de)
AU (1) AU3413501A (de)
CA (1) CA2365606A1 (de)
DE (1) DE60126199T2 (de)
ES (1) ES2275652T3 (de)
HU (1) HUP0201287A3 (de)
WO (1) WO2001062293A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0201284A3 (en) 2000-02-22 2003-02-28 Daiichi Asubio Pharma Co Ltd Preventive or therapeutic drugs for fibrosis containing quinazolindione derivative chymase inhibitors as the active ingredient
WO2001062294A1 (fr) 2000-02-22 2001-08-30 Suntory Limited Medicaments preventifs ou therapeutiques contenant des inhibiteurs de chymase en tant que principe actif, pour traiter des dermatites
EP2463268B1 (de) 2004-12-02 2013-08-28 Daiichi Sankyo Company, Limited 4-(Aminomethyl)benzoesäuren als Zwischenverbindungen für die Herstellung von Chymase-hemmende 1,4-Diazepan-2,5-dion-Verbindungen
MX2008015196A (es) 2006-05-31 2008-12-15 Asubio Pharma Co Ltd Compuesto de anillo de 7 miembros, proceso para producir el mismo, y su uso medico.
DE102009043745A1 (de) 2009-09-30 2011-04-07 Carl Zeiss Microlmaging Gmbh Spektraldetektor mit variabler Filterung durch räumliche Farbtrennung und Laser-Scanning- Mikroskop
CA2784180C (en) 2009-12-25 2014-03-11 Daiichi Sankyo Company, Limited Seven-membered ring compound and pharmaceutical use therefor
US11840543B2 (en) 2017-05-24 2023-12-12 The University Of Queensland Compounds and uses

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6351335A (ja) 1986-08-20 1988-03-04 Fuji Oil Co Ltd 肥満細胞脱顆粒抑制剤
US5199279A (en) 1991-08-13 1993-04-06 Reynolds Martin M Drum contact freezer system and method
JPH05294930A (ja) * 1992-04-21 1993-11-09 Yoshitomi Pharmaceut Ind Ltd スチリル化合物
CA2137832C (en) 1992-06-12 2000-09-26 Dennis J. Hoover Inhibitors of angiotensin i chymase(s) including human heart chymase
JPH08510243A (ja) 1993-05-12 1996-10-29 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー 殺菌・殺カビ性の縮合二環式ピリミジノン類
EP0721944B1 (de) 1994-07-29 2001-01-17 Suntory Limited Imidazolidin-derivate und ihre verwendung
CA2163399A1 (en) * 1994-11-24 1996-05-25 Katsuhiro Kawano Triazine derivative, chymase activity inhibitor and nitric oxide production inhibitor
DE69634122D1 (de) 1995-04-27 2005-02-03 Mitsubishi Pharma Corp Heterocyclische amidverbindungen und deren medizinische verwendung
US5596111A (en) 1995-06-05 1997-01-21 North Dakota State University Method for preparation of carboxylic acids
DE69622148T2 (de) 1995-09-28 2002-10-31 Suntory Limited, Osaka Chinazozin derivate und deren verwendung
JP4199309B2 (ja) 1996-09-06 2008-12-17 日本化薬株式会社 新規アセトアミド誘導体およびプロテアーゼ阻害
JPH1087493A (ja) * 1996-09-18 1998-04-07 Shionogi & Co Ltd セフェム系化合物を含有するキマーゼ阻害剤
JPH10101666A (ja) * 1996-10-02 1998-04-21 Shionogi & Co Ltd 新規ベンゾオキサシクロトリデシン化合物およびそれを含有する医薬組成物
CN1088706C (zh) 1996-10-25 2002-08-07 卫福有限公司 新型杂环酰胺化合物及其医药用途
JPH10245384A (ja) * 1997-03-05 1998-09-14 Teijin Ltd 新規トリアジンスルホン誘導体
EP1055683A4 (de) 1998-02-17 2007-07-25 Nippon Kayaku Kk Neuartiges acetamid-derivat und verwendung desselben
JPH11246437A (ja) * 1998-03-05 1999-09-14 Yoshitomi Pharmaceut Ind Ltd 消化管粘膜保護剤
KR20010089168A (ko) * 1998-08-21 2001-09-29 도리이 신이치로 퀴나졸린 유도체 및 이의 약제학적 용도
JP4491866B2 (ja) * 1999-09-30 2010-06-30 三菱化学株式会社 アシルスルホンアミド誘導体
ATE360423T1 (de) 1999-11-01 2007-05-15 Daiichi Asubio Pharma Co Ltd Verwendung von chymase hemmern gegen vaskuläre lipidablagerung
HUP0201284A3 (en) 2000-02-22 2003-02-28 Daiichi Asubio Pharma Co Ltd Preventive or therapeutic drugs for fibrosis containing quinazolindione derivative chymase inhibitors as the active ingredient
WO2001062294A1 (fr) 2000-02-22 2001-08-30 Suntory Limited Medicaments preventifs ou therapeutiques contenant des inhibiteurs de chymase en tant que principe actif, pour traiter des dermatites

Also Published As

Publication number Publication date
EP1174151A1 (de) 2002-01-23
CN1366459A (zh) 2002-08-28
EP1174151A4 (de) 2003-01-22
AU3413501A (en) 2001-09-03
US6677344B2 (en) 2004-01-13
US20020187989A1 (en) 2002-12-12
HUP0201287A2 (hu) 2002-12-28
HUP0201287A3 (en) 2003-02-28
EP1174151B1 (de) 2007-01-24
KR20010109526A (ko) 2001-12-10
DE60126199D1 (de) 2007-03-15
CA2365606A1 (en) 2001-08-30
DE60126199T2 (de) 2008-02-28
CN1245978C (zh) 2006-03-22
ES2275652T3 (es) 2007-06-16
WO2001062293A1 (fr) 2001-08-30

Similar Documents

Publication Publication Date Title
ATE485265T1 (de) 5-substituierte-2-phenylaminobenzamide als mek- inhibitoren
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
ATE327225T1 (de) Neue verwendung von benzothiazolderivaten
WO2002009702A3 (en) Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
GB0130677D0 (en) Medicaments and novel compounds
EA200601249A1 (ru) Пиперазины, пригодные для лечения боли
ATE352317T1 (de) Therapeutische behandlung von eosinophilie durch verwendung von chymase-inhibitoren als aktiven bestandteilen
ATE550039T1 (de) Mittel zur behandlung von glomerulären erkrankungen
DE60127535D1 (de) Vorbeugende oder therapeutische mittel gegen gastrische oder ösophageale regurgitation
ATE333897T1 (de) Arzneimittel mit chymaseinhibitoren als wirksames mittel zur behandlung von dermatitis mit zweiphasigen hautreaktionen
NZ293691A (en) Use of a medicament containing an anilide compound for treatment of type i allergic diseases
ATE235900T1 (de) Hemmer der subepithelialen turbidität
DE60233578D1 (de) Phosphorenthaltende Verbindugnen mit antithrombitische Wirkung
WO2005035500A3 (en) Therapeutic agents useful for treating pain
WO2004108076A3 (en) Anti-hiv benzamide compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties